Global drugmakers slid on Monday after President Donald Trump vowed to cut U.S. prescription prices to match those in other wealthy countries. In a post on Truth Social, Trump said he would pursue a 59% price cut, a sharper point than the 30% to 80% reduction he had floated a day earlier. The shift jolted investors and sent shares of major pharmaceutical companies lower in premarket trading.
The move signals a harder line on pricing that could hit sales in the world’s largest drug market. It also revives a long-running political fight over how to lower costs for patients without damaging incentives for new treatments.
Market Reaction
Investors moved quickly after the latest comments. Pre-market declines hit a group of large U.S. drugmakers, with losses ranging from 2.2% to 3.7%.
- AbbVie, Amgen, Pfizer, Eli Lilly, and Merck traded lower.
- Losses reflected fears of forced price cuts and margin compression.
- Selling pressure was broad, pulling on global peers and suppliers.
Traders cited uncertainty over timing, scope, and legal paths. Rapid, sweeping changes could alter revenue forecasts across entire product portfolios, especially for high-selling brands in oncology, immunology, and diabetes.
What Was Said
In a Truth Social post on Monday, Trump promised a 59% price slash.
He had pledged a 30% to 80% reduction, “almost immediately,” just a day earlier.
The sharper figure and the speed suggested in the earlier comment stirred concern that action could be attempted through executive steps or emergency measures. Markets often react to the toughest version of a proposal when details are thin.
Policy Context and Precedents
Linking U.S. drug prices to those in other high-income nations is not new. During Trump’s first term, the administration floated a “most favored nation” idea for some Medicare drugs, tying prices to international references. Courts blocked those efforts before they took effect.
Under President Joe Biden, the Inflation Reduction Act created Medicare drug price negotiations for selected medicines and capped out-of-pocket spending for seniors. That law has begun to bite into list prices and rebates for a limited set of drugs, though effects vary by product and timeline.
International reference pricing is common in Europe and Canada. U.S. prices often sit higher than peers, reflecting market exclusivity, fewer direct price controls, and complex rebate structures. A forced alignment could cut U.S. revenue bases for many top-selling therapies.
Industry Stakes and Patient Impact
Pharmaceutical companies argue that high U.S. prices fund research and development. They warn that blunt cuts could slow pipelines, shrink clinical trial budgets, and curb investment, especially in riskier areas like rare diseases.
Patient advocates counter that many Americans skip or ration medicines due to cost. They say lower prices would improve adherence and reduce long-run spending on hospitalizations and complications. They point to other wealthy countries that pay less while maintaining access to many key drugs.
Analysts say the impact would vary. Drugs with little competition and high U.S. list prices could face the steepest resets. Products early in their launch curves are also vulnerable, as price discipline is critical in the first years of commercialization.
Legal and Implementation Questions
Major hurdles remain. Broad price cuts may require legislation, run through lengthy rulemaking, or face litigation from manufacturers and trade groups. Any link to international prices must define which countries, which drug classes, and how updates occur.
Investors will watch for signals on scope:
- Whether the plan targets Medicare only or extends to commercial plans.
- How quickly changes would be phased in.
- Exemptions for rare disease drugs or shortages.
Past efforts have shown that details determine both savings and legal risk. Even with aggressive rhetoric, timelines often stretch as stakeholders push back.
What to Watch Next
Markets are waiting for formal policy text, agency guidance, or a legislative draft. Company commentary on earnings calls will likely quantify exposure and contingency plans. Expect firms to emphasize pipeline resilience, cost controls, and potential portfolio shifts.
For patients, the near-term effects are uncertain. If prices fall, relief could come first for Medicare beneficiaries and then for commercially insured patients as contracts reset. Manufacturers may respond with tighter discounts or narrower access pathways.
The latest pledge has set expectations high and volatility higher. Clear policy design will decide whether the promise translates into lower pharmacy bills or stalls in the courts. For now, drugmakers face a tougher pricing outlook and investors face more headline risk.
Kirstie a technology news reporter at DevX. She reports on emerging technologies and startups waiting to skyrocket.
